Table 2.
Number of subjects (%) with AEs for study day 0 or 28 post-vaccination.
| Solicited/Unsolicited events | Placebo 2 Doses | AERAS-402 (3 x 1010 vp) 2 Doses |
|---|---|---|
| (n=4) (%) | (n=8) (%) | |
| Subjects with at least 1 adverse event | 4 (100.0) | 8 (100.0) |
| Investigations | 4 (100.0) | 8 (100.0) |
| Blood creatine phosphokinase increased | 1 (25.0) | 0 (0.0) |
| Blood creatinine increased | 1 (25.0) | 0 (0.0) |
| Hemoglobin decreased | 4 (100.0) | 8 (100.0) |
| Lymphocytes count increased | 1 (25.0) | 0 (0.0) |
| Neutrophils count decreased | 0 (0.0) | 1 (12.5) |
| Neutrophils count increased | 0 (0.0) | 1 (12.5) |
| White blood cells count increased | 0 (0.0) | 1 (12.5) |
| General disorders and administration site conditions | 0 (0.0) | 5 (62.5) |
| Gastrointestinal disorders | 0 (0.0) | 1 (12.5) |
| Musculoskeletal and connective tissue disorders | 0 (0.0) | 1 (12.5) |
| Respiratory, thoracic and mediastinal disorders | 0 (0.0) | 1 (12.5) |
| Renal and urinary disorders | 1 (25.0) | 0 (0.0) |